Abstract
There are multiple intrinsic mechanisms for diastolic dysfunction ranging from molecular to structural derangements in ventricular myocardium. The molecular mechanisms regulating the progression from normal diastolic function to severe dysfunction still remain poorly understood. Recent studies suggest a potentially important role of core cardio-enriched transcription factors (TFs) in the control of cardiac diastolic function in health and disease through their ability to regulate the expression of target genes involved in the process of adaptive and maladaptive cardiac remodeling. The current relevant findings on the role of a variety of such TFs (TBX5, GATA-4/6, SRF, MYOCD, NRF2, and PITX2) in cardiac diastolic dysfunction and failure are updated, emphasizing their potential as promising targets for novel treatment strategies. In turn, the new animal models described here will be key tools in determining the underlying molecular mechanisms of disease. Since diastolic dysfunction is regulated by various TFs, which are also involved in cross talk with each other, there is a need for more in-depth research from a biomedical perspective in order to establish efficient therapeutic strategies.
Similar content being viewed by others
References
Loffredo FS, Nikolova AP, Pancoast JR, Lee RT (2014) Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res 115:97–107. doi:10.1161/CIRCRESAHA.115.302929
Sharma K, Kass DA (2014) Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 115:79–96. doi:10.1161/CIRCRESAHA.115.302922
Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP et al (2014) New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 35:2797–2815. doi:10.1093/eurheartj/ehu204
Abbate A, Arena R, Abouzaki N, Van Tassell BW, Canada J, Shah K, Biondi-Zoccai G, Voelkel NF (2015) Heart failure with preserved ejection fraction: refocusing on diastole. Int J Cardiol 179:430–440. doi:10.1016/j.ijcard.2014.11.106
Ferrari R, Bohm M, Cleland JG, Paulus WJ, Pieske B, Rapezzi C, Tavazzi L (2015) Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 17:665–671. doi:10.1002/ejhf.304
Oktay AA, Shah SJ (2015) Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons. Curr Cardiol Rev 11:42–52. doi:10.2174/1573403X09666131117131217
Rodrigues PG, Leite-Moreira AF, Falcao-Pires I (2016) Myocardial reverse remodeling: how far can we rewind? Am J Physiol Heart Circ Physiol. doi:10.1152/ajpheart.00696.2015
Gomes AC, Falcao-Pires I, Pires AL, Bras-Silva C, Leite-Moreira AF (2013) Rodent models of heart failure: an updated review. Heart Fail Rev 18:219–249. doi:10.1007/s10741-012-9305-3
Horgan S, Watson C, Glezeva N, Baugh J (2014) Murine models of diastolic dysfunction and heart failure with preserved ejection fraction. J Card Fail 20:984–995. doi:10.1016/j.cardfail.2014.09.001
Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE et al (2007) Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 76:280–291. doi:10.1016/j.cardiores.2007.06.022
Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA (2013) Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res 97:464–471. doi:10.1093/cvr/cvs353
Tong CW, Nair NA, Doersch KM, Liu Y, Rosas PC (2014) Cardiac myosin-binding protein-C is a critical mediator of diastolic function. Pflugers Arch 466:451–457. doi:10.1007/s00424-014-1442-1
Sheng JJ, Feng HZ, Pinto JR, Wei H, Jin JP (2015) Increases of desmin and alpha-actinin in mouse cardiac myofibrils as a response to diastolic dysfunction. J Mol Cell Cardiol. doi:10.1016/j.yjmcc.2015.1010.1035
Rysa J, Leskinen H, Ilves M, Ruskoaho H (2005) Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 45:927–933. doi:10.1161/01.HYP.0000161873.27088.4c
Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H (2008) Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 294:H1804–H1814. doi:10.1152/ajpheart.01078.2007
Regan JA, Mauro AG, Carbone S, Marchetti C, Gill R, Mezzaroma E, Valle Raleigh J, Salloum FN, Van Tassell BW, Abbate A et al (2015) A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. Am J Physiol Heart Circ Physiol 309:H771–H778. doi:10.1152/ajpheart.00282.2015
Franssen C, Gonzalez Miqueo A (2016) The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J 24:259–267. doi:10.1007/s12471-016-0812-z
Ingle KA, Kain V, Goel M, Prabhu SD, Young ME, Halade GV (2015) Cardiomyocyte-specific Bmal1 deletion in mice triggers diastolic dysfunction, extracellular matrix response, and impaired resolution of inflammation. Am J Physiol Heart Circ Physiol 309:H1827–H1836. doi:10.1152/ajpheart.00608.2015
Jia G, Habibi J, DeMarco VG, Martinez-Lemus LA, Ma L, Whaley-Connell AT, Aroor AR, Domeier TL, Zhu Y, Meininger GA et al (2015) Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension 66:1159–1167. doi:10.1161/HYPERTENSIONAHA.115.06015
Kathiriya IS, Nora EP, Bruneau BG (2015) Investigating the transcriptional control of cardiovascular development. Circ Res 116:700–714. doi:10.1161/CIRCRESAHA.116.302832
Nimura K, Kaneda Y (2015) Elucidating the mechanisms of transcription regulation during heart development by next-generation sequencing. J Hum Genet. doi:10.1038/jhg.2015.1084
Kohli S, Ahuja S, Rani V (2011) Transcription factors in heart: promising therapeutic targets in cardiac hypertrophy. Curr Cardiol Rev 7:262–271. doi:10.2174/157340311799960618
Mikhailov AT, Torrado M (2012) In search of novel targets for heart disease: myocardin and myocardin-related transcriptional cofactors. Biochem Res Int 2012:973723. doi:10.1155/2012/973723
Dirkx E, da Costa Martins PA, De Windt LJ (2013) Regulation of fetal gene expression in heart failure. Biochim Biophys Acta 1832:2414–2424. doi:10.1016/j.bbadis.2013.07.023
Fontaine F, Overman J, Francois M (2015) Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles. Cell Regen (Lond) 4:2. doi:10.1186/s13619-015-0015-x
Packham EA, Brook JD (2003) T-box genes in human disorders. Hum Mol Genet 12(Spec No 1):R37–R44. doi:10.1093/hmg/ddg077
Plageman TF Jr, Yutzey KE (2005) T-box genes and heart development: putting the “T” in heart. Dev Dyn 232:11–20. doi:10.1002/dvdy.20201
Papaioannou VE (2014) The T-box gene family: emerging roles in development, stem cells and cancer. Development 141:3819–3833. doi:10.1242/dev.104471
Hatcher CJ, Goldstein MM, Mah CS, Delia CS, Basson CT (2000) Identification and localization of TBX5 transcription factor during human cardiac morphogenesis. Dev Dyn 219:90–95. doi:10.1002/1097-0177(200009)219:1<90:AID-DVDY1033>3.0.CO;2-L
Mori AD, Zhu Y, Vahora I, Nieman B, Koshiba-Takeuchi K, Davidson L, Pizard A, Seidman JG, Seidman CE, Chen XJ et al (2006) Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis. Dev Biol 297:566–586. doi:10.1016/j.ydbio.2006.05.023
Arnolds DE, Liu F, Fahrenbach JP, Kim GH, Schillinger KJ, Smemo S, McNally EM, Nobrega MA, Patel VV, Moskowitz IP (2012) TBX5 drives Scn5a expression to regulate cardiac conduction system function. J Clin Invest 122:2509–2518. doi:10.1172/JCI62617
Georges R, Nemer G, Morin M, Lefebvre C, Nemer M (2008) Distinct expression and function of alternatively spliced Tbx5 isoforms in cell growth and differentiation. Mol Cell Biol 28:4052–4067. doi:10.1128/MCB.02100-07
Yamak A, Georges RO, Sheikh-Hassani M, Morin M, Komati H, Nemer M (2015) Novel exons in the tbx5 gene locus generate protein isoforms with distinct expression domains and function. J Biol Chem 290:6844–6856. doi:10.1074/jbc.M114.634451
Liberatore CM, Searcy-Schrick RD, Yutzey KE (2000) Ventricular expression of tbx5 inhibits normal heart chamber development. Dev Biol 223:169–180. doi:10.1006/dbio.2000.9748
Patel C, Silcock L, McMullan D, Brueton L, Cox H (2012) TBX5 intragenic duplication: a family with an atypical Holt–Oram syndrome phenotype. Eur J Hum Genet 20:863–869. doi:10.1038/ejhg.2012.16
Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, Gessler M, Nemer M, Seidman CE et al (2001) A murine model of Holt–Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 106:709–721. doi:10.1016/S0092-8674(01)00493-7
Al-Qattan MM, Abou Al-Shaar H (2015) Molecular basis of the clinical features of Holt–Oram syndrome resulting from missense and extended protein mutations of the TBX5 gene as well as TBX5 intragenic duplications. Gene 560:129–136. doi:10.1016/j.gene.2015.02.017
Zhu Y, Gramolini AO, Walsh MA, Zhou YQ, Slorach C, Friedberg MK, Takeuchi JK, Sun H, Henkelman RM, Backx PH et al (2008) Tbx5-dependent pathway regulating diastolic function in congenital heart disease. Proc Natl Acad Sci USA 105:5519–5524. doi:10.1073/pnas.0801779105
Antonini-Canterin F, Carerj S, Di Bello V, Di Salvo G, La Carrubba S, Vriz O, Pavan D, Balbarini A, Nicolosi GL (2009) Arterial stiffness and ventricular stiffness: a couple of diseases or a coupling disease? A review from the cardiologist’s point of view. Eur J Echocardiogr 10:36–43. doi:10.1093/ejechocard/jen236
Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T et al (2009) Genome-wide association study of blood pressure and hypertension. Nat Genet 41:677–687. doi:10.1038/ng.384
Zhou YQ, Zhu Y, Bishop J, Davidson L, Henkelman RM, Bruneau BG, Foster FS (2005) Abnormal cardiac inflow patterns during postnatal development in a mouse model of Holt–Oram syndrome. Am J Physiol Heart Circ Physiol 289:H992–H1001. doi:10.1152/ajpheart.00027.2005
Pikkarainen S, Tokola H, Kerkela R, Ruskoaho H (2004) GATA transcription factors in the developing and adult heart. Cardiovasc Res 63:196–207. doi:10.1016/j.cardiores.2004.03.025
Peterkin T, Gibson A, Loose M, Patient R (2005) The roles of GATA-4, -5 and -6 in vertebrate heart development. Semin Cell Dev Biol 16:83–94. doi:10.1016/j.semcdb.2004.10.003
Rysa J, Tenhunen O, Serpi R, Soini Y, Nemer M, Leskinen H, Ruskoaho H (2010) GATA-4 is an angiogenic survival factor of the infarcted heart. Circ Heart Fail 3:440–450. doi:10.1161/CIRCHEARTFAILURE.109.889642
Lepore JJ, Cappola TP, Mericko PA, Morrisey EE, Parmacek MS (2005) GATA-6 regulates genes promoting synthetic functions in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 25:309–314. doi:10.1161/01.ATV.0000152725.76020.3c
Zhao R, Watt AJ, Battle MA, Li J, Bondow BJ, Duncan SA (2008) Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. Dev Biol 317:614–619. doi:10.1016/j.ydbio.2008.03.013
Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, Molkentin JD (2001) The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 276:30245–30253. doi:10.1074/jbc.M102174200
van Berlo JH, Aronow BJ, Molkentin JD (2013) Parsing the roles of the transcription factors GATA-4 and GATA-6 in the adult cardiac hypertrophic response. PLoS ONE 8:e84591. doi:10.1371/journal.pone.0084591
van Berlo JH, Elrod JW, van den Hoogenhof MM, York AJ, Aronow BJ, Duncan SA, Molkentin JD (2010) The transcription factor GATA-6 regulates pathological cardiac hypertrophy. Circ Res 107:1032–1040. doi:10.1161/CIRCRESAHA.110.220764
Oka T, Maillet M, Watt AJ, Schwartz RJ, Aronow BJ, Duncan SA, Molkentin JD (2006) Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res 98:837–845. doi:10.1161/01.RES.0000215985.18538.c4
Prendiville TW, Guo H, Lin Z, Zhou P, Stevens SM, He A, VanDusen N, Chen J, Zhong L, Wang DZ et al (2015) Novel roles of GATA4/6 in the postnatal heart identified through temporally controlled, cardiomyocyte-specific gene inactivation by adeno-associated virus delivery of Cre recombinase. PLoS ONE 10:e0128105. doi:10.1371/journal.pone.0128105
Ishiwata T, Nakazawa M, Pu WT, Tevosian SG, Izumo S (2003) Developmental changes in ventricular diastolic function correlate with changes in ventricular myoarchitecture in normal mouse embryos. Circ Res 93:857–865. doi:10.1161/01.RES.0000100389.57520.1A
Pu WT, Ishiwata T, Juraszek AL, Ma Q, Izumo S (2004) GATA4 is a dosage-sensitive regulator of cardiac morphogenesis. Dev Biol 275:235–244. doi:10.1016/j.ydbio.2004.08.008
Charron F, Paradis P, Bronchain O, Nemer G, Nemer M (1999) Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol 19:4355–4365
McCulley DJ, Black BL (2012) Transcription factor pathways and congenital heart disease. Curr Top Dev Biol 100:253–277. doi:10.1016/B978-0-12-387786-4.00008-7
Zhou B, Ma Q, Kong SW, Hu Y, Campbell PH, McGowan FX, Ackerman KG, Wu B, Tevosian SG, Pu WT (2009) Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart. J Clin Invest 119:1462–1476. doi:10.1172/JCI38723
Rouf R, Greytak S, Wooten EC, Wu J, Boltax J, Picard M, Svensson EC, Dillmann WH, Patten RD, Huggins GS (2008) Increased FOG-2 in failing myocardium disrupts thyroid hormone-dependent SERCA2 gene transcription. Circ Res 103:493–501. doi:10.1161/CIRCRESAHA.108.181487
Miano JM (2003) Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol 35:577–593. doi:10.1016/S0022-2828(03)00110-X
Miano JM, Long X, Fujiwara K (2007) Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol 292:C70–C81. doi:10.1152/ajpcell.00386.2006
Zhang X, Azhar G, Helms S, Burton B, Huang C, Zhong Y, Gu X, Fang H, Tong W, Wei JY (2011) Identification of new SRF binding sites in genes modulated by SRF over-expression in mouse hearts. Gene Regul Syst Biol 5:41–59. doi:10.4137/GRSB.S7457
Miano JM (2010) Role of serum response factor in the pathogenesis of disease. Lab Invest 90:1274–1284. doi:10.1038/labinvest.2010.104
Mikhailov AT, Torrado M (2010) NKX2.5 and SRF in postnatal cardiac remodeling: is there a link? In: Mikhailov AT, Torrado M (eds) Shaping the heart in development and disease. Transworld Research Network, Trivandrum, pp 145–164
Zhang X, Azhar G, Furr MC, Zhong Y, Wei JY (2003) Model of functional cardiac aging: young adult mice with mild overexpression of serum response factor. Am J Physiol Regul Integr Comp Physiol 285:R552–R560. doi:10.1152/ajpregu.00631.2002
Angelini A, Li Z, Mericskay M, Decaux JF (2015) Regulation of connective tissue growth factor and cardiac fibrosis by an SRF/microRNA-133a Axis. PLoS ONE 10:e0139858. doi:10.1371/journal.pone.0139858
Cen B, Selvaraj A, Prywes R (2004) Myocardin/MKL family of SRF coactivators: key regulators of immediate early and muscle specific gene expression. J Cell Biochem 93:74–82. doi:10.1002/jcb.20199
Pipes GC, Creemers EE, Olson EN (2006) The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 20:1545–1556. doi:10.1101/gad.1428006
Parmacek MS (2007) Myocardin-related transcription factors: critical coactivators regulating cardiovascular development and adaptation. Circ Res 100:633–644. doi:10.1161/01.RES.0000259563.61091.e8
Miano JM (2015) Myocardin in biology and disease. J Biomed Res 29:3–19. doi:10.7555/JBR.29.20140151
Huang J, Min L, Cheng L, Yuan LJ, Zhu X, Stout AL, Chen M, Li J, Parmacek MS (2009) Myocardin is required for cardiomyocyte survival and maintenance of heart function. Proc Natl Acad Sci USA 106:18734–18739. doi:10.1073/pnas.0910749106
Torrado M, Centeno C, López E, Mikhailov AT (2009) In-vivo forced expression of myocardin in ventricular myocardium transiently impairs systolic performance in early neonatal pig heart. Int J Dev Biol 53:1457–1467. doi:10.1387/ijdb.072366mt
Kumar A, Crawford K, Close L, Madison M, Lorenz J, Doetschman T, Pawlowski S, Duffy J, Neumann J, Robbins J et al (1997) Rescue of cardiac alpha-actin-deficient mice by enteric smooth muscle gamma-actin. Proc Natl Acad Sci USA 94:4406–4411
Torrado M, Iglesias R, Centeno A, Lopez E, Mikhailov AT (2011) Targeted gene-silencing reveals the functional significance of myocardin signaling in the failing heart. PLoS ONE 6:e26392. doi:10.1371/journal.pone.0026392
Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, Xue P, Pi J, Kleeberger SR, Bell DA (2012) Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res 40:7416–7429. doi:10.1093/nar/gks409
Jaiswal AK (2004) Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36:1199–1207. doi:10.1016/j.freeradbiomed.2004.02.074
Niture SK, Kaspar JW, Shen J, Jaiswal AK (2010) Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244:37–42. doi:10.1016/j.taap.2009.06.009
Li J, Ichikawa T, Janicki JS, Cui T (2009) Targeting the Nrf2 pathway against cardiovascular disease. Expert Opin Ther Targets 13:785–794. doi:10.1517/14728220903025762
Zhou S, Sun W, Zhang Z, Zheng Y (2014) The role of Nrf2-mediated pathway in cardiac remodeling and heart failure. Oxid Med Cell Longev 2014:260429. doi:10.1155/2014/260429
Cho HY, Marzec J, Kleeberger SR (2015) Functional polymorphisms in Nrf2: implications for human disease. Free Radic Biol Med 88:362–372. doi:10.1016/j.freeradbiomed.2015.06.012
Chan K, Lu R, Chang JC, Kan YW (1996) NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci USA 93:13943–13948
Li J, Ichikawa T, Villacorta L, Janicki JS, Brower GL, Yamamoto M, Cui T (2009) Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 29:1843–1850. doi:10.1161/ATVBAHA.109.189480
Xu B, Zhang J, Strom J, Lee S, Chen QM (2014) Myocardial ischemic reperfusion induces de novo Nrf2 protein translation. Biochim Biophys Acta 1842:1638–1647. doi:10.1016/j.bbadis.2014.06.002
Tao G, Kahr PC, Morikawa Y, Zhang M, Rahmani M, Heallen TR, Li L, Sun Z, Olson EN, Amendt BA et al (2016) Pitx2 promotes heart repair by activating the antioxidant response after cardiac injury. Nature. doi:10.1038/nature17959
Erkens R, Kramer CM, Luckstadt W, Panknin C, Krause L, Weidenbach M, Dirzka J, Krenz T, Mergia E, Suvorava T et al (2015) Left ventricular diastolic dysfunction in Nrf2 knock out mice is associated with cardiac hypertrophy, decreased expression of SERCA2a, and preserved endothelial function. Free Radic Biol Med 89:906–917. doi:10.1016/j.freeradbiomed.2015.10.409
Howden R (2013) Nrf2 and cardiovascular defense. Oxid Med Cell Longev 2013:104308. doi:10.1155/2013/104308
Cominacini L, Mozzini C, Garbin U, Pasini A, Stranieri C, Solani E, Vallerio P, Tinelli IA, Fratta Pasini A (2015) Endoplasmic reticulum stress and Nrf2 signaling in cardiovascular diseases. Free Radic Biol Med 88:233–242. doi:10.1016/j.freeradbiomed.2015.05.027
Seymour EM, Bennink MR, Bolling SF (2013) Diet-relevant phytochemical intake affects the cardiac AhR and nrf2 transcriptome and reduces heart failure in hypertensive rats. J Nutr Biochem 24:1580–1586. doi:10.1016/j.jnutbio.2013.01.008
From AM, Scott CG, Chen HH (2010) The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 55:300–305. doi:10.1016/j.jacc.2009.12.003
Liu Q, Wang S, Cai L (2014) Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage. J Diabetes Investig 5:623–634. doi:10.1111/jdi.12250
Chen J, Zhang Z, Cai L (2014) Diabetic cardiomyopathy and its prevention by nrf2: current status. Diabetes Metab J 38:337–345. doi:10.4093/dmj.2014.38.5.337
Semina EV, Reiter R, Leysens NJ, Alward WL, Small KW, Datson NA, Siegel-Bartelt J, Bierke-Nelson D, Bitoun P, Zabel BU et al (1996) Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet 14:392–399. doi:10.1038/ng1296-392
Hjalt TA, Semina EV (2005) Current molecular understanding of Axenfeld–Rieger syndrome. Expert Rev Mol Med 7:1–17. doi:10.1017/S1462399405010082
Zhao CM, Peng LY, Li L, Liu XY, Wang J, Zhang XL, Yuan F, Li RG, Qiu XB, Yang YQ (2015) PITX2 loss-of-function mutation contributes to congenital endocardial cushion defect and Axenfeld–Rieger syndrome. PLoS ONE 10:e0124409. doi:10.1371/journal.pone.0124409
Hjalt TA, Semina EV, Amendt BA, Murray JC (2000) The Pitx2 protein in mouse development. Dev Dyn 218:195–200. doi:10.1002/(SICI)1097-0177(200005)218:1<195:AID-DVDY17>3.0.CO;2-C
Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH, Rotering H, Fortmueller L, Laakmann S, Verheule S et al (2011) PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet 4:123–133. doi:10.1161/CIRCGENETICS.110.958058
Kahr PC, Piccini I, Fabritz L, Greber B, Scholer H, Scheld HH, Hoffmeier A, Brown NA, Kirchhof P (2011) Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissue. PLoS ONE 6:e26389. doi:10.1371/journal.pone.0026389
Hsu J, Hanna P, Van Wagoner DR, Barnard J, Serre D, Chung MK, Smith JD (2012) Whole genome expression differences in human left and right atria ascertained by RNA sequencing. Circ Cardiovasc Genet 5:327–335. doi:10.1161/CIRCGENETICS.111.961631
Torrado M, Franco D, Hernandez-Torres F, Crespo-Leiro MG, Iglesias-Gil C, Castro-Beiras A, Mikhailov AT (2014) Pitx2c is reactivated in the failing myocardium and stimulates myf5 expression in cultured cardiomyocytes. PLoS ONE 9:e90561. doi:10.1371/journal.pone.0090561
Hernandez-Torres F, Franco D, Aranega AE, Navarro F (2015) Expression patterns and immunohistochemical localization of PITX2B transcription factor in the developing mouse heart. Int J Dev Biol 59:247–254. doi:10.1387/ijdb.140224fh
Cox CJ, Espinoza HM, McWilliams B, Chappell K, Morton L, Hjalt TA, Semina EV, Amendt BA (2002) Differential regulation of gene expression by PITX2 isoforms. J Biol Chem 277:25001–25010. doi:10.1074/jbc.M201737200
Kioussi C, Briata P, Baek SH, Rose DW, Hamblet NS, Herman T, Ohgi KA, Lin C, Gleiberman A, Wang J et al (2002) Identification of a Wnt/Dvl/beta-Catenin – > Pitx2 pathway mediating cell-type-specific proliferation during development. Cell 111:673–685. doi:10.1016/S0092-8674(02)01084-X
Venugopalan SR, Amen MA, Wang J, Wong L, Cavender AC, D’Souza RN, Akerlund M, Brody SL, Hjalt TA, Amendt BA (2008) Novel expression and transcriptional regulation of FoxJ1 during oro-facial morphogenesis. Hum Mol Genet 17:3643–3654. doi:10.1093/hmg/ddn258
Vadlamudi U, Espinoza HM, Ganga M, Martin DM, Liu X, Engelhardt JF, Amendt BA (2005) PITX2, beta-catenin and LEF-1 interact to synergistically regulate the LEF-1 promoter. J Cell Sci 118:1129–1137. doi:10.1242/jcs.01706
Ganga M, Espinoza HM, Cox CJ, Morton L, Hjalt TA, Lee Y, Amendt BA (2003) PITX2 isoform-specific regulation of atrial natriuretic factor expression: synergism and repression with Nkx2.5. J Biol Chem 278:22437–22445. doi:10.1074/jbc.M210163200
Toro R, Saadi I, Kuburas A, Nemer M, Russo AF (2004) Cell-specific activation of the atrial natriuretic factor promoter by PITX2 and MEF2A. J Biol Chem 279:52087–52094. doi:10.1074/jbc.M404802200
Zacharias AL, Lewandoski M, Rudnicki MA, Gage PJ (2011) Pitx2 is an upstream activator of extraocular myogenesis and survival. Dev Biol 349:395–405. doi:10.1016/j.ydbio.2010.10.028
Zhou M, Liao Y, Tu X (2015) The role of transcription factors in atrial fibrillation. J Thorac Dis 7:152–158. doi:10.3978/j.issn.2072-1439.2015.01.21
Tessari A, Pietrobon M, Notte A, Cifelli G, Gage PJ, Schneider MD, Lembo G, Campione M (2008) Myocardial Pitx2 differentially regulates the left atrial identity and ventricular asymmetric remodeling programs. Circ Res 102:813–822. doi:10.1161/CIRCRESAHA.107.163188
Tao Y, Zhang M, Li L, Bai Y, Zhou Y, Moon AM, Kaminski HJ, Martin JF (2014) Pitx2, an atrial fibrillation predisposition gene, directly regulates ion transport and intercalated disc genes. Circ Cardiovasc Genet 7:23–32. doi:10.1161/CIRCGENETICS.113.000259
Chinchilla A, Daimi H, Lozano-Velasco E, Dominguez JN, Caballero R, Delpon E, Tamargo J, Cinca J, Hove-Madsen L, Aranega AE et al (2011) PITX2 insufficiency leads to atrial electrical and structural remodeling linked to arrhythmogenesis. Circ Cardiovasc Genet 4:269–279. doi:10.1161/CIRCGENETICS.110.958116
Franco D, Chinchilla A, Aranega AE (2012) Transgenic insights linking pitx2 and atrial arrhythmias. Front Physiol 3:206. doi:10.3389/fphys.2012.00206
Franco D, Chinchilla A, Daimi H, Dominguez JN, Aranega A (2011) Modulation of conductive elements by Pitx2 and their impact on atrial arrhythmogenesis. Cardiovasc Res 91:223–231. doi:10.1093/cvr/cvr078
Franco D, Christoffels VM, Campione M (2014) Homeobox transcription factor Pitx2: the rise of an asymmetry gene in cardiogenesis and arrhythmogenesis. Trends Cardiovasc Med 24:23–31. doi:10.1016/j.tcm.2013.06.001
Huang Y, Wang C, Yao Y, Zuo X, Chen S, Xu C, Zhang H, Lu Q, Chang L, Wang F et al (2015) Molecular basis of gene-gene interaction: cyclic cross-regulation of gene expression and post-GWAS gene–gene interaction involved in atrial fibrillation. PLoS Genet 11:e1005393. doi:10.1371/journal.pgen.1005393
Torrado M, Franco D, Lozano-Velasco E, Hernandez-Torres F, Calvino R, Aldama G, Centeno A, Castro-Beiras A, Mikhailov A (2015) A microRNA-transcription factor blueprint for early atrial arrhythmogenic remodeling. Biomed Res Int 2015:263151. doi:10.1155/2015/263151
Santerre RF, Bales KR, Janney MJ, Hannon K, Fisher LF, Bailey CS, Morris J, Ivarie R, Smith CK 2nd (1993) Expression of bovine myf5 induces ectopic skeletal muscle formation in transgenic mice. Mol Cell Biol 13:6044–6051
Edwards JG, Lyons GE, Micales BK, Malhotra A, Factor S, Leinwand LA (1996) Cardiomyopathy in transgenic myf5 mice. Circ Res 78:379–387. doi:10.1161/01.RES.78.3.379
Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu S, Wang L, Lee A et al (2012) Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 4:130ra147. doi:10.1126/scitranslmed.3003552
Su D, Jing S, Guan L, Li Q, Zhang H, Gao X, Ma X (2014) Role of Nodal-PITX2C signaling pathway in glucose-induced cardiomyocyte hypertrophy. Biochem Cell Biol 92:183–190. doi:10.1139/bcb-2013-0124
Scimia MC, Sydnes KE, Zuppo DA, Koch WJ (2014) Methods to improve cardiac gene therapy expression. Expert Rev Cardiovasc Ther 12:1317–1326. doi:10.1586/14779072.2014.967683
Nair N, Gupta S, Collier IX, Gongora E, Vijayaraghavan K (2014) Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF? Int J Cardiol 175:395–399. doi:10.1016/j.ijcard.2014.06.027
Wang F, Yang XY, Zhao JY, Yu LW, Zhang P, Duan WY, Chong M, Gui YH (2014) miR-10a and miR-10b target the 3′-untranslated region of TBX5 to repress its expression. Pediatr Cardiol 35:1072–1079. doi:10.1007/s00246-014-0901-y
Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J et al (2009) MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119:2772–2786. doi:10.1172/JCI36154
Han M, Yang Z, Sayed D, He M, Gao S, Lin L, Yoon S, Abdellatif M (2012) GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovasc Res 93:645–654. doi:10.1093/cvr/cvs001
Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, Olson EN (2008) MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 22:3242–3254. doi:10.1101/gad.1738708
Wang DZ (2010) MicroRNAs in cardiac development and remodeling. Pediatr Cardiol 31:357–362. doi:10.1007/s00246-010-9641-9
Liao XH, Wang N, Zhao DW, Zheng DL, Zheng L, Xing WJ, Zhou H, Cao DS, Zhang TC (2014) NF-kappaB (p65) negatively regulates myocardin-induced cardiomyocyte hypertrophy through multiple mechanisms. Cell Signal 26:2738–2748. doi:10.1016/j.cellsig.2014.08.006
Wang K, Long B, Zhou J, Li PF (2010) MiR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem 285:11903–11912. doi:10.1074/jbc.M109.098004
Nair N, Kumar S, Gongora E, Gupta S (2013) Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem 376:33–40. doi:10.1007/s11010-012-1546-x
Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, Geer RC, He J, Gwadz M, Hurwitz DI et al (2015) CDD: NCBI’s conserved domain database. Nucleic Acids Res 43:D222–D226. doi:10.1093/nar/gku1221
Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, Rothrock CR, Eapen RS, Hirayama-Yamada K, Joo K et al (2003) GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424:443–447. doi:10.1038/nature01827
Kodo K, Nishizawa T, Furutani M, Arai S, Ishihara K, Oda M, Makino S, Fukuda K, Takahashi T, Matsuoka R et al (2012) Genetic analysis of essential cardiac transcription factors in 256 patients with non-syndromic congenital heart defects. Circ J 76:1703–1711. doi:10.1253/circj.CJ-11-1389
Wang C, Cao D, Wang Q, Wang DZ (2011) Synergistic activation of cardiac genes by myocardin and Tbx5. PLoS ONE 6:e24242. doi:10.1371/journal.pone.0024242
Shang Y, Yoshida T, Amendt BA, Martin JF, Owens GK (2008) Pitx2 is functionally important in the early stages of vascular smooth muscle cell differentiation. J Cell Biol 181:461–473. doi:10.1083/jcb.200711145
Martin DM, Amendt BA, Brown NA (2010) Pitx2 in cardiac left–right asymmetry and human disease. In: Rosenthal N, Harvey RP (eds) Heart development and regeneration, vol 1. Academic Press, New York, pp 307–320
Diedrichs H, Chi M, Boelck B, Mehlhorn U, Schwinger RH (2004) Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure. Eur J Heart Fail 6:3–9. doi:10.1016/j.ejheart.2003.07.007
Chang J, Wei L, Otani T, Youker KA, Entman ML, Schwartz RJ (2003) Inhibitory cardiac transcription factor, SRF-N, is generated by caspase 3 cleavage in human heart failure and attenuated by ventricular unloading. Circulation 108:407–413. doi:10.1161/01.CIR.0000084502.02147.83
Torrado M, Lopez E, Centeno A, Medrano C, Castro-Beiras A, Mikhailov AT (2003) Myocardin mRNA is augmented in the failing myocardium: expression profiling in the porcine model and human dilated cardiomyopathy. J Mol Med 81:566–577
Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L et al (2011) Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60:625–633. doi:10.2337/db10-1164
Acknowledgments
This work was supported in part by funds from the Institute of Health Sciences and by a grant (GRC 2013/061) from the Autonomic Government of Galicia, Spain.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The manuscript does not contain clinical studies or patient data.
Conflict of interest
The authors have declared that no competing interests exist.
Rights and permissions
About this article
Cite this article
Mikhailov, A.T., Torrado, M. Myocardial transcription factors in diastolic dysfunction: clues for model systems and disease. Heart Fail Rev 21, 783–794 (2016). https://doi.org/10.1007/s10741-016-9569-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-016-9569-0